This article has been
cited by other articles in ScienceCentral.
Dear Editor:
During the coronavirus disease 2019 (COVID-19) pandemic, expanding data on the presence of neurological complications has increased the interest in neurological involvement of COVID-19 and its possible pathophysiological mechanisms. Recently, many studies have been published showing that COVID-19 may cause neurological disorders [
1-
3]. The incidence of neurological disorders has been reported higher in severe patients requiring intensive care admission [
2]. In COVID-19 patients, timely recognition and intervention of neurological disorders is crucial to improve outcomes. For this reason, we aimed to share the characteristics of neurological diseases in critically-ill COVID-19 patients who were admitted to our COVID-intensive care unit (ICU) between March 21, 2020 and March 21, 2021 for 1-year period.
In our ICU, 16 (4.9%) of 328 critically ill confirmed COVID-19 patients manifested with severe neurological diseases. Neurological findings were present in half of the patients at hospital admission and in the remaining eight patients, neurological problems were detected after ICU admission, in five of them after failure of awakening from cessation of sedation and in three of them after development of hemiparesis. Patients’ characteristics are shown in
Table 1. There were 13 cases (81.3%) with ischemic stroke (IS), 10 of these patients had no previous history of IS. There was one case with Guillain-Barre syndrome, one with intracranial hemorrhage, and one with meningitis. IS was the most common neurological disease in our registry similar to other studies. However, when the risk factors of 13 patients regarding IS were evaluated, there was only one patient who did not have any risk factors for IS. Other patients had at least one risk factor for IS. There was hypertension in six patients, diabetes mellitus in five patients, cardiac disease in four patients, cerebrovascular disease in three patients and a long-term intensive care stay with renal failure and septic shock in one patient. Overall mortality was 37.5% in patients with neurological disease, whereas the 1-year mortality was 32.3% in our COVID-19 cohort.
The fact that detailed neurological evaluation could not be performed during a pandemic in the context of ICU, indicates that the incidence of neurological diseases might even be more than that reported, increasing morbidity and mortality. Patients can present with neurological complications before development of respiratory symptoms and signs during the COVID-19 course. Suspicion threshold for neurological complications should be low in cases of encephalopathy even if focal neurological deficits were not detected in COVID-19 patients. Although many studies have been published to reveal the relationship between COVID-19 and stroke, the majority of patients with IS during COVID-19 have advanced age and co-morbidities similar to our patients [
4,
5]. In a study of a high-volume center examining the relationship between COVID-19 and stroke, usual causes of stroke were found in most of the stroke cases. Moreover, all patients with an acute stroke without a usual etiology presented a severe infection requiring mechanical ventilation [
5]. We believe that detailed etiological evaluations will give more accurate results in terms of determining COVID-19 related neurological complications. Therefore, more studies are needed to define the real incidence of neurological complications of COVID-19 and to clarify the underlying mechanism and causality between COVID-19 and neurological diseases.